Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19.
Sergey V EfimovNatallia V MatsiyeuskayaOlga V BoytsovaLuydmila Yu AkhievaElena V KuntsevichAnastasia A TroshinaElena I KvasovaAnton A TikhonovNadezhda F KhomyakovaFrancisco HarrisonJean-François RossiTimothy Colin HardmanPublished in: Drugs in context (2022)
AZB combined with standard of care was safe and well tolerated. An apparent clinical improvement could not be fully evaluated due to the lack of a direct control group; further assessment of AZB for the treatment of COVID-19 in a randomized, placebo-controlled study is warranted.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- open label
- ejection fraction
- healthcare
- newly diagnosed
- chronic kidney disease
- clinical trial
- palliative care
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- randomized controlled trial
- magnetic resonance imaging
- quality improvement
- magnetic resonance
- combination therapy
- phase ii study
- double blind
- patient reported outcomes
- rectal cancer
- affordable care act
- contrast enhanced
- locally advanced
- smoking cessation